デフォルト表紙
市場調査レポート
商品コード
1304299

がん治療薬市場:薬剤クラスタイプ別、適応症別、地域別:市場規模、シェア、展望、機会分析、2023年~2030年

Cancer Drugs Market, By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and By Indication By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 150 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
がん治療薬市場:薬剤クラスタイプ別、適応症別、地域別:市場規模、シェア、展望、機会分析、2023年~2030年
出版日: 2023年06月21日
発行: Coherent Market Insights
ページ情報: 英文 150 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

がんは、体の細胞の一部が制御不能に増殖し、体の他の部分に転移する最も致死的な疾患です。化学療法、ホルモン療法、標的がん治療薬、免疫療法薬、ビスフォスフォネート製剤などのがん治療薬は、さまざまなタイプのがんを治療するために使用されます。このように、がんの負担の増加に伴い、安全で効果的ながん治療薬の需要も世界的に急ピッチで増加しています。

市場力学:

がんの有病率の増加、老年人口の増加、安全で効果的ながん治療薬に対する高い需要、がんやがん治療薬に対する人々の意識の高まり、がん治療センターの増加などは、予測期間中に世界のがん治療薬市場の成長を増大させると予想される要因です。

本調査の主な特徴

  • 本レポートでは、世界のがん治療薬市場を詳細に分析し、2022年を基準年とした予測期間(2023-2030年)の市場規模および複合年間成長率(CAGR%)を掲載しています。
  • また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場に対する魅力的な投資提案のマトリックスについて解説しています。
  • また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
  • 企業ハイライト、製品ポートフォリオ、主要ハイライト、財務実績、戦略などの以下のパラメータに基づいて、世界のがん治療薬市場における主要企業をプロファイルしています。
  • 本調査の対象となる主要企業には、Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson(Janssen Global Services, LLC), among others.が含まれます。
  • 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
  • 世界のがん治療薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
  • 利害関係者は、世界のがん治療薬市場を分析する際に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場概況

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
  • コヒーレント・オポチュニティ・マップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 世界中で増加するがんの負担
    • がん治療薬の副作用
    • 安全で効果的な医薬品への需要の高まり
  • 影響分析
  • 主なハイライト
  • 規制シナリオ
  • 製品上市/承認
  • PEST分析
  • ポーターズ分析
  • 合併・買収シナリオ

第4章 世界のがん治療薬市場-コロナウイルス(COVID-19)パンデミックの影響

  • COVID-19疫学
  • 供給サイドと需要サイドの分析
  • 経済的影響

第5章 がん治療薬の世界市場:薬剤クラスタイプ別、2023-2030年

  • 化学療法
  • 標的療法
  • ホルモン療法

第6章 がん治療薬の世界市場、適応症別、2023-2030年

  • イントロダクション
  • 肺がん
  • 胃がん
  • 大腸がん
  • 乳がん
  • 前立腺がん
  • 肝臓がん
  • 食道がん
  • 子宮頸がん
  • 腎臓がん
  • 膀胱がん
  • その他のがん

第7章 がん治療薬の世界市場、地域別、2023年~2030年

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第8章 競合情勢

  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Celgene Corporation
  • AstraZeneca PLC
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson(Janssen Global Services, LLC)

第9章 セクション

  • 調査手法
  • 出版社について
目次
Product Code: CMI5888

Cancer is a most lethal disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. Cancer drugs, such as chemotherapy, hormone therapies, targeted cancer drugs, immunotherapy drugs, and bisphosphonates, among others, are used to treat different types of cancer. Thus, with the rise in burden of cancer, the demand for safe and effective cancer drugs is also increasing with a rapid pace, worldwide.

Market Dynamics:

Increasing prevalence of cancer, growing geriatric population, high demand for safe and effective cancer drugs, increasing awareness among people about a cancer and cancer drugs, and increasing number of cancer treatment centres are factors expected to augment the growth of the global cancer drugs market during the forecast period.

For instance, according to the American Cancer Society (ACS), in 2023, more than 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. While, in 2022, around 1.9 Billion new cancer cases and 609,360 cancer deaths were projected to occur in the U.S. Moreover, according to the cancer report by Indian Council of Medical Research (ICMR), India's cancer cases could increase by 12% in the next five years, with around 1.5 Billion people projected to suffer from the non-communicable disease by 2025, up from 1.39 Billion in 2020.

Key features of the study:

  • This report provides in-depth analysis of the global cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson (Janssen Global Services, LLC), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer drugs market.

Detailed Segmentation:

  • Global Cancer Drugs Market, By Drug Class Type:
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy (Biologic Therapy)
    • Hormonal Therapy)
  • Global Cancer Drugs Market, By Indication:
    • Lung Cancer
    • Stomach Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Prostate Cancer
    • Liver Cancer
    • Esophagus Cancer
    • Cervical Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Other Cancer
  • Global Cancer Drugs Market, By Geography:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Celgene Corporation
    • AstraZeneca PLC
    • Astellas Pharma Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson (Janssen Global Services, LLC)

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class Type
    • Market Snapshot, By Indication
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing burden of cancer across the globe
    • Adverse effects of cancer drugs
    • Growing demand for safe and effective drugs
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Cancer Drugs Market, By Drug Class Type, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Targeted Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
    • Immunotherapy (Biologic Therapy)
  • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Hormonal Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

6. Global Cancer Drugs Market, By Indication, 2023-2030, (US$ Bn)

  • Intzroduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Stomach Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Liver Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Esophagus Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Cervical Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Kidney Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Bladder Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Other Cancers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

7. Global Cancer Drugs Market, By Region, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)

8. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Celgene Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson (Janssen Global Services, LLC)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us